Paper36922679
LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.
Malvi P and 7 others. Oncogene, 2023. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition. Papers, record 36922679. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36922679
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA Helicases | Major topic |
| Melanoma | Major topic |
| Animals | |
| Mice | |
| Apoptosis | |
| Lim Kinases | |
| Poly-ADP-Ribose Binding Proteins | |
| RNA Helicases | |
| RNA Recognition Motif Proteins | |
| Proteoglycans |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA013148 | NIH |
Source NIH RePORTER
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25589936 | Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma. | ACS Med Chem Lett | 2015 | https://conductscience.org/library/papers/25589936 | PubMed |
| 2 | 10613909 | Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2. | J Cell Biol | 1999 | https://conductscience.org/library/papers/10613909 | PubMed |
| 3 | 24509905 | Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer. | Cancer Res | 2014 | https://conductscience.org/library/papers/24509905 | PubMed |
| 4 | 35176431 | The roles of G3BP1 in human diseases (review). | Gene | 2022 | https://conductscience.org/library/papers/35176431 | PubMed |
| 5 | 18442402 | The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. | BMC Med Genomics | 2008 | https://conductscience.org/library/papers/18442402 | PubMed |
| 6 | 15728811 | EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15728811 | PubMed |
| 7 | 24265155 | Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24265155 | PubMed |
| 8 | 28581515 | GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. | Oncogene | 2017 | https://conductscience.org/library/papers/28581515 | PubMed |
| 9 | 25932675 | Targeting cancer with kinase inhibitors. | J Clin Invest | 2015 | https://conductscience.org/library/papers/25932675 | PubMed |
| 10 | 34568836 | Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. | Nat Cancer | 2021 | https://conductscience.org/library/papers/34568836 | PubMed |
| 11 | 34212149 | Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. | RSC Chem Biol | 2021 | https://conductscience.org/library/papers/34212149 | PubMed |
| 12 | 28407145 | GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. | Nucleic Acids Res | 2017 | https://conductscience.org/library/papers/28407145 | PubMed |
| 13 | 34795264 | G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. | Nat Commun | 2021 | https://conductscience.org/library/papers/34795264 | PubMed |
| 14 | 30259761 | A comprehensive review of protein kinase inhibitors for cancer therapy. | Expert Rev Anticancer Ther | 2018 | https://conductscience.org/library/papers/30259761 | PubMed |
| 15 | 30207743 | The roles and mechanisms of G3BP1 in tumour promotion. | J Drug Target | 2019 | https://conductscience.org/library/papers/30207743 | PubMed |
| 16 | 21447797 | Resistance to MEK inhibitors: should we co-target upstream? | Sci Signal | 2011 | https://conductscience.org/library/papers/21447797 | PubMed |
| 17 | 34002056 | Kinase drug discovery 20 years after imatinib: progress and future directions. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/34002056 | PubMed |
| 18 | 31734559 | Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer. | Mol Ther Nucleic Acids | 2019 | https://conductscience.org/library/papers/31734559 | PubMed |
| 19 | 34109132 | Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach. | Front Oncol | 2021 | https://conductscience.org/library/papers/34109132 | PubMed |
| 20 | 18505921 | Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. | Mol Cancer Res | 2008 | https://conductscience.org/library/papers/18505921 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42066056 | Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader. | ACS Chem Biol | 2026 | https://conductscience.org/library/papers/42066056 | PubMed |
| 42007146 | Banxia Xiexin Decoction inhibits chemoresistance in gastric cancer by regulating BMSC-derived exosome-mediated G3BP1-YWHAZ protein interaction. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42007146 | PubMed |
| 40775397 | LIMK2 promotes centrosome clustering and cancer progression by activating MST4-mediated phosphorylation of NPM1. | Oncogene | 2025 | https://conductscience.org/library/papers/40775397 | PubMed |
| 39361252 | Regulation and signaling of the LIM domain kinases. | Bioessays | 2025 | https://conductscience.org/library/papers/39361252 | PubMed |
| 39281564 | The role of ESM1 in the lipids metabolic reprogramming and angiogenesis of lung adenocarcinoma cells. | Heliyon | 2024 | https://conductscience.org/library/papers/39281564 | PubMed |
| 39100690 | Stress granules in cancer: Adaptive dynamics and therapeutic implications. | iScience | 2024 | https://conductscience.org/library/papers/39100690 | PubMed |
| 37141984 | LIMK2: A Multifaceted kinase with pleiotropic roles in human physiology and pathologies. | Cancer Lett | 2023 | https://conductscience.org/library/papers/37141984 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| LIMK2 | 3985 | PubTator's text mining | https://conductscience.org/library/genes/3985 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36922679
GET https://conductscience.org/api/papers/v1/36922679/references?page=2